Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Vigil Neuroscience, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/08/2023 8-K Quarterly results
Docs: "Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/10/2023 8-K Quarterly results
Docs: "Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update"
05/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors"
03/30/2023 8-K Quarterly results
03/21/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/10/2023 8-K Quarterly results
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Slide Presentation, (furnished herewith)"
12/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team"
12/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP"
12/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Slide Presentation, (furnished herewith)",
"Slide Presentation, (furnished herewith)"
08/12/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
07/28/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/20/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vigil Neuroscience Expands Leadership Team and Board of Directors"
03/25/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights"
02/25/2022 8-K Quarterly results
01/11/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 6, 2022 VIGIL NEUROSCIENCE, INC. Delaware 001-41200 85-1880494 Vigil Neuroscience, Inc. 1 Broadway, 7th Floor, Suite 07-300 Cambridge, Massachusetts 254-4445 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement...",
"Third Amended and Restated Certificate of Incorporation of Vigil Neuroscience, Inc",
"Amended and Restated Bylaws of Vigil Neuroscience, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy